• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖与肠道微生物组:努力探寻因果关系。

Obesity and the gut microbiome: Striving for causality.

机构信息

Division of Molecular Immunology, Cincinnati Children's Hospital Research Foundation, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.

出版信息

Mol Metab. 2012 Aug 3;1(1-2):21-31. doi: 10.1016/j.molmet.2012.07.002. eCollection 2012.

DOI:10.1016/j.molmet.2012.07.002
PMID:24024115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3757651/
Abstract

The gut microbiome has been proposed to play a causal role in obesity. Here, we review the historical context for this hypothesis, highlight recent key findings, and critically discuss issues central to further progress in the field, including the central epistemological problem for the field: how to define causality in the relationship between microbiota and obesity phenotypes. Definition of such will be critical for the field to move forward.

摘要

肠道微生物群被认为在肥胖中起因果作用。在这里,我们回顾了这一假设的历史背景,强调了最近的关键发现,并批判性地讨论了该领域进一步发展的核心问题,包括该领域的中心认识论问题:如何定义微生物群与肥胖表型之间的关系中的因果关系。这种定义对于该领域的发展至关重要。

相似文献

1
Obesity and the gut microbiome: Striving for causality.肥胖与肠道微生物组:努力探寻因果关系。
Mol Metab. 2012 Aug 3;1(1-2):21-31. doi: 10.1016/j.molmet.2012.07.002. eCollection 2012.
2
Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.评估人体肥胖和糖尿病中肠道微生物组的因果关系。
Endocr Rev. 2018 Apr 1;39(2):133-153. doi: 10.1210/er.2017-00192.
3
Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.肠道微生物群与儿童肥胖/非酒精性脂肪性肝病。
J Formos Med Assoc. 2019 Mar;118 Suppl 1:S55-S61. doi: 10.1016/j.jfma.2018.11.006. Epub 2018 Dec 1.
4
Gut Microbiota as a Therapeutic Target for Metabolic Disorders.肠道微生物群作为代谢紊乱的治疗靶点。
Curr Med Chem. 2018;25(9):984-1001. doi: 10.2174/0929867324666171009121702.
5
The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.肠道微生物群作为2型糖尿病高血糖预防和治疗的靶点:从当前的人类证据到未来的可能性
Diabetologia. 2017 Jun;60(6):943-951. doi: 10.1007/s00125-017-4278-3. Epub 2017 Apr 22.
6
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章:肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
7
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.肠道微生物组和饮食在非酒精性脂肪性肝病发病机制中的作用。
Clin Mol Hepatol. 2021 Jan;27(1):22-43. doi: 10.3350/cmh.2020.0129. Epub 2020 Dec 10.
8
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢产物在肥胖及肥胖相关代谢紊乱中的作用:当前的证据和观点。
Curr Obes Rep. 2019 Sep;8(3):317-332. doi: 10.1007/s13679-019-00352-2.
9
The guts of obesity: progress and challenges in linking gut microbes to obesity.肥胖的内在机制:将肠道微生物与肥胖联系起来的进展与挑战
Discov Med. 2015 Feb;19(103):81-8.
10
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.肠道微生物群与人类非酒精性脂肪性肝病:从代谢紊乱中解析微生物特征。
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297. doi: 10.1038/s41575-020-0269-9. Epub 2020 Mar 9.

引用本文的文献

1
A permutable MLP-like architecture for disease prediction from gut metagenomic data.一种可置换的类似于多层感知机的架构,用于从肠道宏基因组数据中进行疾病预测。
BMC Bioinformatics. 2024 Jul 24;25(1):246. doi: 10.1186/s12859-024-05856-w.
2
The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease.糖尿病肾病早晚期的肠道微生物组成。
Microbiol Spectr. 2023 Aug 17;11(4):e0038223. doi: 10.1128/spectrum.00382-23. Epub 2023 Jun 21.
3
Metabolic reconstitution of germ-free mice by a gnotobiotic microbiota varies over the circadian cycle.无菌小鼠的共生微生物群的代谢重建随昼夜节律而变化。
PLoS Biol. 2022 Sep 20;20(9):e3001743. doi: 10.1371/journal.pbio.3001743. eCollection 2022 Sep.
4
Phage Cocktail Targeting STEC O157:H7 Has Comparable Efficacy and Superior Recovery Compared with Enrofloxacin in an Enteric Murine Model.噬菌体鸡尾酒靶向 STEC O157:H7 的疗效与恩诺沙星相当,在肠道鼠模型中恢复效果更佳。
Microbiol Spectr. 2022 Jun 29;10(3):e0023222. doi: 10.1128/spectrum.00232-22. Epub 2022 May 10.
5
Systemic lupus erythematosus as a genetic disease.系统性红斑狼疮作为一种遗传疾病。
Clin Immunol. 2022 Mar;236:108953. doi: 10.1016/j.clim.2022.108953. Epub 2022 Feb 9.
6
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.低热量饮食联合 NNMT 抑制在 DIO 小鼠中建立独特的微生物组。
Sci Rep. 2022 Jan 10;12(1):484. doi: 10.1038/s41598-021-03670-5.
7
Xanthohumol Requires the Intestinal Microbiota to Improve Glucose Metabolism in Diet-Induced Obese Mice.黄腐酚需要肠道微生物群来改善饮食诱导肥胖小鼠的葡萄糖代谢。
Mol Nutr Food Res. 2021 Nov;65(21):e2100389. doi: 10.1002/mnfr.202100389. Epub 2021 Oct 12.
8
Comparison of 16S and whole genome dog microbiomes using machine learning.使用机器学习对16S和全基因组犬微生物群进行比较。
BioData Min. 2021 Aug 21;14(1):41. doi: 10.1186/s13040-021-00270-x.
9
Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation.抗逆转录病毒疗法(ART)治疗的 HIV 患者具有独特的肠道微生物组,提示其与慢性炎症有关。
Microbiol Spectr. 2021 Sep 3;9(1):e0070821. doi: 10.1128/Spectrum.00708-21. Epub 2021 Aug 11.
10
Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota.由(SARS-CoV-2)感染引起的冠状病毒病(COVID-19):人类肠道微生物组的真正挑战。
Front Cell Infect Microbiol. 2020 Dec 9;10:575559. doi: 10.3389/fcimb.2020.575559. eCollection 2020.

本文引用的文献

1
Human gut microbiome viewed across age and geography.人类肠道微生物组在年龄和地理上的差异。
Nature. 2012 May 9;486(7402):222-7. doi: 10.1038/nature11053.
2
Regulated virulence controls the ability of a pathogen to compete with the gut microbiota.调控毒力控制病原体与肠道微生物群落竞争的能力。
Science. 2012 Jun 8;336(6086):1325-9. doi: 10.1126/science.1222195. Epub 2012 May 10.
3
The impact of the gut microbiota on human health: an integrative view.肠道微生物群对人类健康的影响:综合观点。
Cell. 2012 Mar 16;148(6):1258-70. doi: 10.1016/j.cell.2012.01.035.
4
Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling.组织因子和 PAR1 促进微生物群诱导的肠道血管重塑。
Nature. 2012 Mar 11;483(7391):627-31. doi: 10.1038/nature10893.
5
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.炎症小体介导的微生态失调调控非酒精性脂肪性肝病和肥胖的进展。
Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.
6
Fecal microbiota transplantation and emerging applications.粪便微生物移植与新兴应用。
Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):88-96. doi: 10.1038/nrgastro.2011.244.
7
Experimental and analytical tools for studying the human microbiome.研究人类微生物组的实验和分析工具。
Nat Rev Genet. 2011 Dec 16;13(1):47-58. doi: 10.1038/nrg3129.
8
Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice.肠道微生物群是 TLR2 敲除小鼠胰岛素抵抗的关键调节因子。
PLoS Biol. 2011 Dec;9(12):e1001212. doi: 10.1371/journal.pbio.1001212. Epub 2011 Dec 6.
9
Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota.高脂肪饮食引起的代谢适应与肠道微生物群的变化有关。
Gut. 2012 Apr;61(4):543-53. doi: 10.1136/gutjnl-2011-301012. Epub 2011 Nov 22.
10
Drosophila microbiome modulates host developmental and metabolic homeostasis via insulin signaling.果蝇微生物组通过胰岛素信号调节宿主的发育和代谢稳态。
Science. 2011 Nov 4;334(6056):670-4. doi: 10.1126/science.1212782.